|
Research and Markets: Triple Analysis: Melanoma, Pancreatic Cancer and …
Business Wire (press release) … addition of the “Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies” report to their offering. This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of … |
Cell Therapeutics Inc (CTIC): Cell Therapeutics: Solid Pipeline, Partnerships …Seeking AlphaFurthermore, Pixuvri is also in Phase III (PIX306) in combination with rituximab, for aggressive NHL or grade 3 lymphoma patients who are not eligible for ste…
Industry Today (press release) |
Global Cancer Monoclonal Antibodies Market Analysis
Industry Today (press release) Bharatbook.com announces a new report on “Global Cancer Monoclonal Antibodies Pipeline Analysis” which gives investment opportunity in the Cancer Monoclonal Antibodies market based upon development process. Posted via Industry Today. Are you … |
MedscapeBiologics Projected to Transform Uveitis TreatmentMedscapeThese include the anti-CD20 inhibitors rituximab and ocrelizumab, the anti-TNF inhibitors certolizumab and golimumab, the interleukin-6 inhibitor tocilizumab, the interleukin-1 inhibitor…
One Year Access to Oncology, Biosimilars, Antibodies, Proteins and Vaccines …DigitalJournal.comThis subscription provides access during one year to all existing and new reports produced by La Merie Publishing and listed in the online store, including…
One Year Access to Oncology, Biosimilars, Antibodies, Proteins and Vaccines …PR Newswire (press release)This subscription provides access during one year to all existing and new reports produced by La Merie Publishing and listed in the online store, …
Drug Discovery & Development |
Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …
FiercePharma The orphan tag applies to use of Treanda for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within 6 months of treatment with rituximab or a regimen containing rituximab. Orphan status is granted to therapies intended to … Teva Gets Additional Exclusivity for TreandaDrug Discovery & Development Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) Teva gains additional regulatory exclusivity for TreandaThe Pharma Letter |
Drug Discovery & Development |
Teva Gets Additional Exclusivity for Treanda
Drug Discovery & Development … Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. FDA grants Teva’s Treanda orphan drug statusGlobes Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …FiercePharma Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) |
Drug Discovery & Development |
FDA grants Teva’s Treanda orphan drug status
Globes … that the US Food and Drug Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with … Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) Teva Pharma Reports Addl. Regulatory Exclusivity For TREANDA For InjectionNASDAQ |
Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release)TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months…